在阿尔茨海默氏症进展过程中,USP10在tau病理和神经元命运中的双重调控作用
Masahiko Takahashi1, Hiroki Kitaura2,3, Asa Nakahara2
1Division of Virology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Molecular and cellular biology
|December 9, 2025
概括
乌比基特异性蛋白酶10 (USP10) 对于阿尔茨海默病 (AD) 中的神经元存活至关重要. 降低USP10会在晚期AD中恶化Tau病理和神经元损失.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是tau蛋白聚合,神经元细胞死亡和认知能力下降.
- 陶病理是AD进展中神经元细胞死亡和大脑缩的关键驱动因素.
研究的目的:
- 为了研究在阿尔茨海默病 (AD) Tau 病理和神经元活力中泛素特异性蛋白酶10 (USP10) 的作用.
- 阐明将USP10下调与AD中Tau积累和神经元亡联系在一起的机制.
主要方法:
- 分析晚期AD患者死后大脑中USP10表达的分析.
- 使用特定于大脑的USP10淘汰赛小鼠和P301S-Tau转基因小鼠,研究USP10功能.
- 评估神经元亡,大脑缩和tau水平与USP10表达和tau病理有关的情况.
主要成果:
- 在晚期AD大脑中,USP10表达减少了严重的Tau积累,与增加的神经元亡相关.
- 在AD下调的USP10可能是通过选择性自的p62-介导降解的结果.
- 脑特异性淘汰导致神经元亡和脑缩的增加.
- 在P301S-Tau小鼠中,异合体 Usp10 淘汰会降低Tau水平并改善早期生存,表明阶段依赖的效应.
结论:
- USP10是阿尔茨海默病中Tau病理和神经元生存的关键调节者.
- 在AD中USP10的作用取决于阶段,其减少加剧了晚期神经元损失,尽管可能减轻了早期tau负担.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
The Proteasome
10.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.0K
The Unfolded Protein Response
6.2K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
6.2K


